Assessing the effect of intrathecal midazolam in the quality and duration of analgesia in cesarean section

Cesarean Section (C/S) is one of the most common surgical procedures in the world for which intrathecal anesthesia is a method of choice. This study was carried out to evaluate the effect of Midazolam in quality and duration of analgesia in S/C. This was a double blind randomized trial study in which 124 women with C/S were divided into 2 groups. In the first group Bupivacain plus normal saline was used (control group) and in the second one Bupivacain plus intrathecal Midazolam was injected (interventional group). The beginning and the end of sensation block, severity of pain before and after operation, vital signs (V/S), time of requesting the first analgesic and morbidity in both groups were evaluated and recorded. Independent t-test, k 2, Mann-Withny and Fisher exact test were used to analyze the data. This study showed that the duration of analgesia, 142.18 ± 55.19 minutes (M) in the control group and 178.06 ± 77.33 M in the case group, was significantly different. The severity of pain 15 M after operation was 1.21 ± 1.32 in the control group and 0.45 ± 1.11 in the intervention group. 120 M after operation it was 4.97 ± 2.1 in control group and 2 ± 1.64 in the intervention group representing a significant reduction in pain perception (p<0.007). Sensory block started 1.72 ± 0.052 M faster in the intervention group. Vital sign changes were not significantly different between the two groups. Nausea and vomiting were more frequent in the interventional group. Intrathecal Midazolam plus Bupivacain is a suitable drug to decrease pain and increase the duration of analgesia in C/S.